Haite Biotechnology: Announcement on the Election of Independent Directors

Securities code: 300683 Securities abbreviation: Haite Biotechnology Announcement number: 2025-053

Wuhan Haite Biopharmaceutical Co., Ltd.

Announcement on the Election of Independent Directors

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.

Wuhan Haite Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the second meeting of the Nomination Committee of the Ninth Board of Directors and the sixth meeting of the Ninth Board of Directors on December 29, 2025, and reviewed and approved the "Proposal on the Election of Independent Directors", which still needs to be submitted to the company's shareholders' meeting for review. The specific situation is now announced as follows:

In accordance with the provisions of the Company Law, Articles of Association and relevant laws and regulations, upon nomination by the company's board of directors and approval by the nomination committee of the board of directors, the company's board of directors intends to elect Mr. Shi Xianwang and Mr. Zeng Junkai as independent directors of the ninth session of the company's board of directors (see the attachment for detailed resumes), and at the same time appoint Mr. Shi Xianwang as the convener of the audit committee and member of the nomination committee. The term starts from the date of approval by the shareholders' meeting and ends on the expiration of the ninth session of the company's board of directors. After Mr. Shi Xianwang and Mr. Zeng Junkai were elected as the company's directors, the total number of concurrently serving senior managers and employee representatives on the company's board of directors shall not exceed one-half of the company's total directors, which is in compliance with relevant laws, regulations and normative documents.

As of the date of this announcement, independent director candidate Mr. Shi Xianwang has obtained the independent director qualification certificate. Independent director candidate Mr. Zeng Junkai has not yet obtained the independent director qualification certificate. He has promised to participate in the latest independent director training and obtain the independent director qualification certificate recognized by the Shenzhen Stock Exchange. The qualifications and independence of independent directors must be reviewed and approved by the Shenzhen Stock Exchange before being submitted to the company's shareholders' meeting for review.

The company's board of directors and independent directors have fully understood the educational background, work experience, work performance and other basic information of Mr. Shi Xianwang and Mr. Zeng Junkai, and believe that their role as independent directors complies with relevant laws and regulations and the provisions of the Articles of Association. They have not been punished by the China Securities Regulatory Commission and other relevant departments or stock exchanges, and have not been listed as persons subject to execution for breach of trust.

Announcement is hereby made.

Wuhan Haite Biopharmaceutical Co., Ltd.

Attachment December 30, 2025

1. Mr. Zeng Junkai, born in April 1984, holds a doctoral degree. From August 2015 to July 2020, he served as an assistant professor at the University of Kansas Business School, mainly engaged in corporate finance and capital market-related research and undergraduate course teaching; from July 2019 to July 2020, he served as a financial economist at the Federal Reserve Bank of the United States, participating in policy research work; from August 2020 to July 2023, he served as an associate professor of finance at the School of Management, National Taiwan University, mainly responsible for academic research and graduate teaching; 2023 Joined the Business School of the Chinese University of Hong Kong in 2025 and served as an associate professor of the Department of Accounting from August 2023 to July 2025, mainly engaged in research and teaching related to capital markets, corporate innovation and financial statement analysis; from August 2025, he served as a professor of the Department of Accounting and co-director of the Faculty Development Center, responsible for faculty development and related academic affairs.

As of the date of this announcement, Mr. Zeng Junkai does not hold any shares in the company, and has no related relationship with other directors, senior managers, shareholders or actual controllers holding more than 5% of the company's shares; there is no Article 3.2.3 of the Company Law and Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies. The circumstances stipulated in the article; have not been punished by the China Securities Regulatory Commission and other relevant departments or disciplinary sanctions by stock exchanges; have not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations, but no clear conclusion has been made; have not been publicized by the China Securities Regulatory Commission on the illegal and untrustworthy information public inquiry platform in the securities and futures markets or included in the list of dishonest persons subject to execution by the people's court; their employment meets the requirements of the Company Law and other relevant laws, regulations and normative documents.

2. Mr. Shi Xianwang, born in January 1968, holds a doctoral degree. From July 1996 to present, he has been a teacher at the Accounting School of Zhongnan University of Economics and Law. He is the leader of the accounting discipline of the Accounting School of Wuhan University and the leader of the "Industry and Finance Integration" teaching reform team. The main research areas are basic financial accounting theory, accounting standards theory and practice, environmental accounting and other fields. He has published dozens of papers in journals such as "Accounting Research" and "Audit Research". He once served as an independent director of Wuhan Jinyun Laser Co., Ltd. and Sunflower Pharmaceutical Group Co., Ltd., and currently serves as an independent director of Wuhan Mingde Biotechnology Co., Ltd. and Thalys Medical Technology Group Co., Ltd.

As of the date of this announcement, Mr. Shi Xianwang does not hold any shares in the company, and has no relationship with other directors, senior managers, shareholders or actual controllers holding more than 5% of the company's shares; there is no Article 3.2.3 of the Company Law and Shenzhen Stock Exchange Self-Discipline Supervision Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies. The circumstances stipulated in the article; have not been punished by the China Securities Regulatory Commission and other relevant departments or disciplinary sanctions by stock exchanges; have not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations, but no clear conclusion has been made; have not been publicized by the China Securities Regulatory Commission on the illegal and untrustworthy information public inquiry platform in the securities and futures markets or included in the list of dishonest persons subject to execution by the people's court; their employment meets the requirements of the Company Law and other relevant laws, regulations and normative documents.